MarginsXMarginsX
Home › Data Desk › Prime Medicine Inc. revenue rises 243.9% in the quarter to Sep 30, 2026

MarginsX Data Desk · Quarterly results · Early-stage clinical trials

Prime Medicine Inc. revenue rises 243.9% in the quarter to Sep 30, 2026

Prime Medicine Inc. (PRME) filed its 10-Q on Nov 12, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 12, 2026.

Bar chart of Prime Medicine Inc.'s quarterly revenue from Jun 30, 2024 to Sep 30, 2026, the latest quarter highlighted.

Revenue and margins

Revenue was $4.2M, up 243.9% from $1.2M in the same period a year earlier, which ended Sep 30, 2025. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

The net loss was $39.0M. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

Balance sheet

Cash was $54.9M at Sep 30, 2026, against $47.5M at Jun 30, 2026. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

Shares outstanding were 181.9 million, against 181.4 million at Jun 30, 2026, a rise of 0.3%. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

At its recent quarterly burn of $39.4M, that cash lasts about 4.2 months, by our estimate from its XBRL cash flows. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

The stock

The Nasdaq screener puts its market value at $707.7M. (Nasdaq stock screener, Nov 13, 2026)

Prime Medicine Inc. sets up an at-the-market share program

The 424B5 that Prime Medicine Inc. (PRME) filed on Nov 10, 2026 describes an at-the-market program, in which an agent sells new shares into the market over time. (SEC EDGAR, 424B5, Nov 10, 2026)

Prime Medicine Inc. files for an at-the-market share sale

Prime Medicine Inc. (PRME) filed a 424B5 on Nov 12, 2026 whose text describes an at-the-market offering, shares sold into the market over time through a sales agent. (SEC EDGAR, 424B5, Nov 12, 2026)

Follow it up

The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/PRME)

The filing on SEC EDGAR. (sec.gov)

The filing in the MarginsX reader. (MarginsX reader)

Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.

Facts behind this article

FactValueSourceAs of
NamePrime Medicine Inc.Source2026-11-13
Revenue change2.439 %Source2026-11-12
Revenue4,213,000 USDSource2026-11-12
Revenue a year earlier1,225,000 USDSource2026-11-12
Period endSep 30, 2026Source2026-11-12
WhoPrime Medicine Inc. (PRME)Source2026-11-13
SymbolPRMESource2026-11-13
Form10-QSource2026-11-12
FiledNov 12, 2026Source2026-11-12
A year earlier endSep 30, 2025Source2026-11-12
Net loss39,043,000 USDSource2026-11-12
Net income-39,043,000 USDSource2026-11-12
Cash54,886,000 USDSource2026-09-30
Cash prior47,451,000 USDSource2026-11-12
Prior endJun 30, 2026Source2026-11-12
Shares181,921,405 sharesSource2026-11-12
Shares prior181,376,856 sharesSource2026-11-12
Dilution0.003 %Source2026-11-12
Burn abs39,423,750 USDSource2026-09-30
Burn-39,423,750 USDSource2026-09-30
Runway4.2 monthsSource2026-09-30
Cap707,674,265 USDSource2026-11-13
Form424B5Source2026-11-10
FiledNov 10, 2026Source2026-11-10

Sources

Automated from SEC filings and market data. No AI. For information only. Not investment advice.

Discuss in MarginsX More from the Data Desk

More on MarginsX

Companies in this article

Topics

Related Data Desk stories

Every Data Desk article: /desk · RSS